Poseida Therapeutics Stock
Genome engineering-enabled therapeutics
Sign up today and learn more about Poseida Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Poseida Therapeutics Stock
Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need. It has demonstrated proof-of-principle that validates the potential of its differentiated genome engineering technologies and their therapeutic applications. The company's technology platforms have broad applicability and Poseida’s long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases.
Funding History
| December 2015 | $23.0M |
|---|---|
| August 2017 | $11.2M |
| October 2017 | $19.8M |
| April 2018 | $30.5M |
| April 2019 | $142M |
Management
Chief Technology Officer
Paiman Peter Ghoroghchian
Chief Executive Officer
Eric Ostertag
Chief Medical Officer
Matthew Spear
Chief Human Resources Officer
Kristin Martin
President and Chief Operating Officer
Nishan de Silva
Chief Business Officer and Chief Financial Officer
Mark J. Gergen
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
